Pharmacokinetics and Tolerability of CKD-386 vs Co-administered Drugs in Healthy Volunteers

Phase 1, randomised, open-label trial of ezetimibe + rosuvastatin + telmisartan in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t at 72 hours and Maximum Plasma Concentration at 72 hours. Started Feb 2021; status: completed.